PM8002 in the Treatment of Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures; 2. Male or female aged 18 to 75 years; 3. Patients with malignant tumor confirmed by histology or cytology; 4. The toxicity of previous anti-tumor therapy has not been alleviated； 5. Adequate organ function； 6. ECOG score was 0-1; 7. Expected survival \>=12 weeks; 8. According to RECIST 1.1 criteria, at least 1 measurable lesion that has not been previously treated locally. Exclusion Criteria: 1. History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study; 2. Evidence of major coagulopathy or other obvious risk of bleeding; 3. Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy; 4. Patients with uncontrolled brain metastases should be excluded from this clinical trial; 5. Patients ever experienced other active malignant tumors within 5 years prior to the study treatment; 6. Prior allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 7. Known history of alcohol abuse, psychotropic drug abuse or drug abuse; 8. Syphilis antibody positive; 9. Patients with active tuberculosis (TB) are excluded; 10. Pregnant or lactating women; 11. Other conditions lead to inappropriate to participate in this study as judged by the investigator.